< img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4285980&fmt=gif" />
en
Search
Home
Customer Testimonials
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
API Form and Solid-State Research
Crystallization Development
Pre-formulation Studies
Formulation and Analytical Development
GMP Manufacturing
Clinical Supply
Crystal Bio
Competitive Advantages
Lab & Equipment
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
About Us
Our Company
Our History
Our People
Our Partner
Resources
News & Events
Knowledge Hub
Webinar Series
Careers
Talent Recruitment
Contact Us
Home
Customer Testimonials
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
Solid-State Characterization/FAST
pKa/LogP/LogD Measurements
Stability and Solubility Studies
In-Silico PBPK Modeling and Simulation
API Form and Solid-State Research
Solid Form Screening and Selection
Single Crystal Growth & Structure Determination
Solid-State NMR Analysis
Crystallization Development
Crystallization Development
Chiral Separation
Pre-formulation Studies
Comprehensive Physicochemical Property Evaluation
Excipient Selection and Compatibility Studies
Formulations for PK/Efficacy/Tox Studies
Animal Dosing Vehicle Selection
Amorphous Solid Dispersions
Formulation and Analytical Development
Formulation Development
Oral Solid Dosage Forms
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Pediatric Formulation (Mini-tablet)
Analytical Chemistry
GMP Manufacturing
Clinical and Commercial Manufacturing
FIH-PMF-FMF Manufacturing
Clinical Supply
Crystal Bio
Competitive Advantages
Lab & Equipment
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
About Us
Our Company
Our History
Our People
Our Partner
Resources
News & Events
News
Events
Knowledge Hub
Technical Articles
Presentations
Case Studies
Whitepaper
ASD Series
Biologics
Webinar Series
Crystal Pharmatech Formulation Forum
2023-Mol2Med™ First-Time-Right Approach Webinar Series
Selecting the Right API Form and Formulation
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
Advanced Characterization: Tools for Accelerating Molecules to Medicine
Crystal Bio Webinar
Careers
Talent Recruitment
Contact Us
E-mail us
+1-609-604-8303
bd_global@crystalpharmatech.com
cn
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
API Form and Solid-State Research
Crystallization Development
Pre-formulation Studies
Formulation and Analytical Development
GMP Manufacturing
Clinical Supply
Solid-State Characterization/FAST
pKa/LogP/LogD Measurements
Stability and Solubility Studies
In-Silico PBPK Modeling and Simulation
Solid Form Screening and Selection
Single Crystal Growth & Structure Determination
Solid-State NMR Analysis
Crystallization Development
Chiral Separation
Comprehensive Physicochemical Property Evaluation
Excipient Selection and Compatibility Studies
Formulations for PK/Efficacy/Tox Studies
Animal Dosing Vehicle Selection
Amorphous Solid Dispersions
Formulation Development
Oral Solid Dosage Forms
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Pediatric Formulation (Mini-tablet)
Analytical Chemistry
Clinical and Commercial Manufacturing
FIH-PMF-FMF Manufacturing
Crystal Bio
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
About Us
Our Company
Our History
Our People
Our Partner
Resources
News & Events
Knowledge Hub
Webinar Series
News
Events
Technical Articles
Presentations
Case Studies
Whitepaper
ASD Series
Biologics
Crystal Pharmatech Formulation Forum
2023-Mol2Med™ First-Time-Right Approach Webinar Series
Selecting the Right API Form and Formulation
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
Advanced Characterization: Tools for Accelerating Molecules to Medicine
Crystal Bio Webinar
Careers
Contact Us
Home
Resources
Knowledge Hub
Presentations
Preclinical and Tox Formulation Development
The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
Related CRO & CDMO Services
Solid-State Characterization/FAST
Clinical and Commercial Manufacturing
Mol2Med™ Integrated Services
Latest News about Crystal Pharmatech
News
13 Nov 2024
Improving the Manufacture of mRNA Biologics
Technical Articles
17 Oct 2024
Concerned about mRNA -LNP Integrity during International Shipping?
Technical Articles
06 Aug 2024
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
API Form and Solid-State Research
Crystallization Development
Pre-formulation Studies
Formulation and Analytical Development
GMP Manufacturing
Clinical Supply
Technology
Quick Links
About Us
Events
Contact Us
bd_global@crystalpharmatech.com
+1-609-604-8303
U.S
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China, 215123
Sitemap
Privacy Policy
API Form and Solid-State Research
Solid Form Screening and Selection
Single Crystal Growth & Structure Determination
Solid-State NMR Analysis
Analytical Chemistry
Pre-formulation Studies
Formulation Development
Clinical and Commercial Manufacturing
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
Quick Links
About Us
Technical Articles
Events
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com
+1-609-604-8303
+1-609-604-8303
Your browser does not support VBScript!
